Should I Buy COCP? COCP 2026 Analysis

Should You Buy Cocrystal Pharma Inc (COCP) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

0.970

1 Day change

12.79%

52 Week Range

2.670

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: the primary trend is bearish (SMA_200 > SMA_20 > SMA_5) and downside momentum is still building (MACD histogram negative and expanding).
Even though the stock is deeply oversold (RSI_6 ~18) and could bounce, there is no Intellectia buy signal today to justify an impatient entry.
Insider buying is a supportive datapoint, but the latest quarter shows worsening losses with effectively no revenue, which keeps this in high-risk/speculative territory.
Practical read: avoid new buys here; if already holding, risk of further drift below support is meaningful.

Technical Analysis

Intellectia Proprietary Trading Signals
AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.
Trend: Bearish structure (SMA_200 > SMA_20 > SMA_5) indicates sustained downtrend.
Momentum: MACD histogram = -0.0137 (below 0) and negatively expanding → selling pressure is still increasing.
Mean-reversion: RSI_6 = 18.067 → very oversold; a short-term bounce is possible but not confirmed.
Key levels: Pivot 1.018 (needs reclaim for improvement); Support S1 0.964 then S2 0.931; Resistance R1 1.071 and R2 1.104.
Near-term pattern odds: modeled outcome suggests ~-1.97% next week bias, with only modest positive skew over a month (+1.97%).

Positive Catalysts

- Pre-market strength (+4.08%) suggests some near-term dip-buying/mean-reversion interest.
- Insiders are Buying: buying amount up +469.57% over the last month (supportive sentiment signal).
- Extreme oversold RSI increases the probability of a reflex bounce from the 0.96–0.93 support zone.

Neutral/Negative Catalysts

- No news in the recent week → no clear event-driven catalyst to reverse the downtrend.
- Technicals remain bearish: negative/expanding MACD and bearish moving-average stack.
- If price loses S1 (0.964), next support is S2 (0.931), increasing risk of another leg down.
- Hedge funds are Neutral with no significant trend over the last quarter (no institutional tailwind indicated).

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: 0 (0.00% YoY) → no visible top-line traction.
Net income: -2,049,000 (down -58.51% YoY) → losses worsened.
EPS: -0.19 (down -61.22% YoY) → profitability trend deteriorated.
Overall: financials do not currently support a durable bullish re-rating; price action is more likely sentiment/technical-driven than fundamentals-driven.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price-target change data was provided, and there’s no recent news summary to infer fresh Wall Street positioning.
Wall Street pros/cons view (based on available data only):
- Pros: insider buying suggests internal confidence.
- Cons: lack of revenue and worsening losses make it difficult for analysts to justify sustained upside without a clear catalyst or pipeline milestone (not provided here).
Politicians/Influential figures: No recent congress trading data available in the last 90 days.

1 Analyst Rating

Wall Street analysts forecast COCP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COCP is 10 USD with a low forecast of 10 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.860

Low

Averages

High

Current: 0.860

Low

Averages

High

H.C. Wainwright

Buy

downgrade

$7 -> $6

AI Analysis

2025-06-21

Reason